Welcome to our dedicated page for Biolargo news (Ticker: BLGO), a resource for investors and traders seeking the latest updates and insights on Biolargo stock.
BioLargo, Inc. develops and commercializes sustainable technologies across cleantech, environmental engineering, water treatment and life sciences. Company updates commonly cover its Aqueous Electrostatic Concentrator, a PFAS treatment technology designed to remove and collect per- and polyfluoroalkyl substances from liquid streams, as well as engineering services and project work in water, wastewater, remediation and minerals processing.
BioLargo news also follows subsidiary activity, including Clyra Medical Technologies and its FDA-cleared wound care products based on Copper-Iodine Complex Technology, distribution partnerships for ViaCLYR, investor communications, annual operating results, and commercialization updates across medical, environmental and battery-related business lines.
BioLargo (OTCQX:BLGO) reported that its patented Aqueous Electrostatic Concentrator (AEC) has treated more than two million gallons of PFAS-contaminated water over more than six months of commercial operation at the municipal drinking water facility in Lake Stockholm, New Jersey. Installed in January 2026, the system has consistently removed over 99% of PFAS, delivering effluent below all applicable New Jersey Department of Environmental Protection and U.S. EPA standards while generating significantly less PFAS-laden waste than conventional granular activated carbon systems, which can lower hazardous waste disposal and operating costs for the utility.
According to BioLargo, the Lake Stockholm site now functions as a commercial reference installation for prospective customers. The AEC is being monitored and tested under a 12‑month NJDEP and U.S. EPA program, and BioLargo plans to share third‑party performance data as it becomes available. The company is also pursuing additional municipal and industrial opportunities and views Lake Stockholm as a platform for its collaboration strategy with global water treatment company Aquatech.
BioLargo (OTCQX: BLGO) announced it has joined the New Jersey PFAS Partnership Innovation Consortium (NJ PFAS-PIC), a New Jersey Institute of Technology-led initiative launched in April 2026 to accelerate development, validation, and deployment of technologies for per- and polyfluoroalkyl substances (PFAS).
BioLargo also reported that Tonya Chandler, President of its subsidiary BioLargo Equipment Solutions & Technologies (BEST), has been appointed to the consortium’s Board of Directors, placing the company alongside NJIT, Princeton, Rutgers, Stevens, the New Jersey Department of Environmental Protection, major water utilities, and engineering and environmental firms in guiding PFAS detection, treatment, decontamination, management, and commercialization efforts.
According to BioLargo, membership in NJ PFAS-PIC builds on its prior PFAS work in New Jersey, including a commercial installation of its patented Aqueous Electrostatic Concentrator (AEC) at the Lake Stockholm municipal water facility, and creates opportunities for collaboration on technology demonstrations, regulatory validation, grant-funded research, and commercialization initiatives focused on advanced PFAS treatment solutions.
BioLargo (OTCQX:BLGO) announced that Tonya Chandler, President of subsidiary BioLargo Equipment Solutions & Technologies (BEST), will lead a seven-hour continuing education workshop, “PFAS 101 - Everything You Didn't Want to Know About PFAS,” at the 41st Annual Tri-State Seminar on Monday, August 3, 2026, at the South Point Hotel & Casino in Las Vegas.
This will be Chandler’s fourth consecutive year teaching at Tri-State, a major water industry event that drew nearly 4,800 participants in its 2025 edition. The PFAS 101 course is designed to give water professionals a practical, plain-language grounding in PFAS chemistry, health impacts, regulatory drivers, and treatment options, reflecting BioLargo’s field experience in PFAS collection, destruction, and disposal.
BioLargo (OTCQX:BLGO) announced that its PFAS treatment technology and leadership are featured in the Q1/Q2 2026 edition of The Disruptive Quarterly, titled “Water and Our Common Heritage: Facing the Challenge of Forever Chemicals.” The issue brings together environmental attorneys, researchers, industry innovators, and artists focused on protecting clean water from PFAS contamination.
According to BioLargo, the publication includes an article by Tonya Chandler, President of BioLargo Equipment Solutions and Technologies, and a transcript of CEO Dennis Calvert’s keynote on PFAS at the Norwegian Embassy in Washington, D.C. BioLargo’s PFAS platform centers on its patented Aqueous Electrostatic Concentrator (AEC), designed to rapidly and affordably remove and concentrate PFAS from contaminated water.
BioLargo (OTCQX:BLGO) announced the formation of subsidiary BioLargo CPG to relaunch CupriDyne®-based consumer pet products under a new, yet-to-be-named brand. The move follows the marketing success of CupriDyne products previously licensed to Pooph, which generated more than $125 million in pet-care sales.
BioLargo plans a digital-first strategy, selling direct-to-consumer and via online marketplaces such as Amazon, and intends to expand from pet odor control into broader household odor and cleaning products. According to Grand View Research, the U.S. pet odor control and clean-up market was about $6.47 billion in 2023, projected to reach $8.87 billion by 2030. Management highlights that BioLargo will now own the brand and control marketing and distribution.
BioLargo (OTCQX:BLGO) announced that its engineering unit, BioLargo Engineering, Science & Technologies (BLEST), received $1.4 million in U.S. Air Force contract renewals over 12 months. The contracts extend multi-year air quality and environmental compliance work at five Air Force bases in New Mexico and Arizona.
BLEST continues as a subcontractor, providing regulatory compliance, permitting, testing, air data management, reporting, and inventory management. According to BioLargo, these recurring contracts support a base of repeatable engineering revenue alongside larger projects and product sales.
BioLargo (OTCQX: BLGO) subsidiary Clyra Medical signed an exclusive distribution agreement with Al-Hikma FZCO to commercialize ViaCLYR™ across the Gulf Cooperation Council, the Levant, North Africa, and adjacent markets. The deal includes territory exclusivity tied to performance and cooperative country-level regulatory work is underway.
ViaCLYR™ uses Clyra's Clyrasept™ Copper-Iodine Complex Solution (CICS) as a broad-spectrum antimicrobial for wound irrigation. The partners plan coordinated regulatory filings and commercial rollout across a region serving over 500 million people.
BioLargo (OTCQX:BLGO) signed a non-exclusive memorandum of understanding with Aquatech on May 4, 2026 to advance commercialization of BioLargo's Aqueous Electrostatic Concentrator (AEC) for PFAS treatment.
AEC concentrates and immobilizes PFAS onto membranes without producing a secondary concentrated liquid waste stream; the MOU targets integration of AEC as a concentration and collection step within Aquatech's end-to-end PFAS flowsheets worldwide.
BioLargo (OTCQX: BLGO) announced CEO Dennis P. Calvert will participate in a town hall on May 5, 2026 at 1:00 PM PT on the BioLargo Shareholder Community Discord. The meeting will include a brief company update and shareholder Q&A.
The meeting will be recorded and a transcript will be filed on Form 8-K before market open the following day. Shareholders may pre-submit questions via the Reddit announcement and are encouraged to join the Discord in advance.
BioLargo (OTCQX:BLGO) announced that BioLargo Engineering, Science & Technologies won a $1.2 million contract to design a pilot-scale minerals processing facility to remediate and repurpose a legacy mineral waste deposit in the western United States.
The design phase will take approximately six months; the overall program could progress to full-scale commercial production over an approximate two- to three-year timeframe, subject to successful pilot results and milestone approvals.